Search Results | Clinical Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

Clin Cancer Res (2018) 24 (24): 6195–6203.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-1542

Published: 13 December 2018

View article

Includes: Supplementary data

Journal Articles

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Clin Cancer Res (2017) 23 (18): 5489–5501.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-3216

Published: 14 September 2017

View article

Includes: Supplementary data

Journal Articles

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Monique B. Nilsson, Uma Giri, Jayanthi Gudikote, Ximing Tang, Wei Lu, Hai Tran, Youhong Fan, Andrew Koo, Lixia Diao, Pan Tong, Jing Wang, Roy Herbst, Bruce E. Johnson, Andy Ryan, Alan Webster, Philip Rowe, Ignacio I. Wistuba, John V. Heymach

Clin Cancer Res (2016) 22 (8): 1940–1950.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1994

Published: 14 April 2016

View article

Includes: Supplementary data

Journal Articles

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

Erick Riquelme, Milind Suraokar, Carmen Behrens, Heather Y. Lin, Luc Girard, Monique B. Nilsson, George Simon, Jing Wang, Kevin R. Coombes, J. Jack Lee, Waun Ki Hong, John Heymach, John D. Minna, Ignacio I. Wistuba

Clin Cancer Res (2014) 20 (14): 3849–3861.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-1916

Published: 14 July 2014

View article

Includes: Supplementary data

Journal Articles

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Clin Cancer Res (2013) 19 (1): 279–290.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-1558

Published: 02 January 2013

View article

Includes: Supplementary data

Journal Articles

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

Clin Cancer Res (2009) 15 (10): 3484–3494.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-2904

Published: 18 May 2009

View article

Journal Articles

Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors

Premal H. Thaker, Sertac Yazici, Monique B. Nilsson, Kenji Yokoi, Rachel Z. Tsan, Junqin He, Sun-Jin Kim, Isaiah J. Fidler, Anil K. Sood

Clin Cancer Res (2005) 11 (13): 4923–4933.

DOI: https://doi.org/10.1158/1078-0432.CCR-04-2060

Published: 06 July 2005

View article

NARROW

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors

Email alerts

AACR Journals

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only